Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2

INTRODUCTION: A second generation of prophylactic human papillomavirus (HPV) vaccines based on the minor capsid protein L2 has entered clinical trials as promising alternative to meet the gaps left out by the current vaccines concerning type-restricted protection, high costs and low penetrance in im...

Descripción completa

Detalles Bibliográficos
Autores principales: Mariz, Filipe Colaco, Putzker, Kerstin, Sehr, Peter, Müller, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663238/
https://www.ncbi.nlm.nih.gov/pubmed/38022617
http://dx.doi.org/10.3389/fimmu.2023.1272018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663238/
https://www.ncbi.nlm.nih.gov/pubmed/38022617
http://dx.doi.org/10.3389/fimmu.2023.1272018

Ejemplares similares